Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis?

Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis? - Alpha blockers and Multiple Sclerosis (MS)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON47090

Enrollment

Registered

2016-01-21

Start date

2016-02-11

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder dysfunction in MS bladder dysfunction in Multiple Sclerosis

Interventions

One group receives the alpha blocker Silodosin during 6 weeks while the second group is treated with placebo during the same period.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Female - Age >= 18 years - Any form of MS - Residual urine 60 ml - 250 ml - Adequate understanding of the Dutch language

Exclusion criteria

Exclusion criteria: - Dependency of wheel chair - Being bedridden - Indwelling catheter - Clean intermittent catheterization - Acute attack of MS - Current treatment with an alpha-blocker - Pregnancy/breastfeeding - Severe kidney dysfunction - Orthostatic hypotension

Design outcomes

Primary

Measure	Time frame
Residual urine, measured within 10 minutes after a voluntary void at t=0 and t=6 weeks.	—

Secondary

Measure	Time frame
- Quality of life (questionnaire: Qualiveen) at t=0 and t=6 weeks. - Symptom scores of voiding complaints (questionnaires: UDI-6 and IIQ-7) at t=0 and t=6 weeks.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)